LUND, Sweden, May 27, 2021 /PRNewswire/ -- Immunovia, a
diagnostic company that develops highly accurate blood tests for
the early detection of cancer and autoimmune diseases, today
announced that it will host a key opinion leader (KOL) event on
IMMray™ PanCan-d, its blood test for early detection of pancreatic
cancer which will be launched as a laboratory developed test (LDT)
in the US by Immunovia Inc.
The live webcast for investors, analysts and media will feature
a panel discussion with three KOLs that each one bring their
perspective on the clinical use of a blood-based test for early
detection of pancreatic cancer in different high-risk groups:
- Dr. Stephen Pereira, Professor
of Hepatology and Gastroenterology, University College London
- Dr. James Farrell, Professor of
Medicine at Yale School of Medicine and
Director of the Yale Center for Pancreatic Diseases at Yale New
Haven Health
- Dr. Geoffrey Burns, MD, FAAFP,
Renaissance Family Medicine of Wellesley,
Massachusetts, USA
Moderator for the panel discussion will be Dr. Thomas King, Medical Director, Immunovia
Inc.
A corporate overview will be presented by Patrik Dahlen, CEO Immunovia.
There will be room for attendees to ask questions to the
panelists during the event.
The Immunovia KOL event details as follows:
Thursday June 10, 2021, at
16.00-17.30 CET
Dial-in numbers:
Belgium: +3224035852
Denmark: +4578150107
France: +33170750721
Germany: +4969222220377
Norway: +4723963688
Sweden: +46850558365
Switzerland: +41225675632
The Netherlands: +31207219496
United Kingdom: +443333009274
United States: +18335268398
Link to the webcast:
https://financialhearings.com/event/13917
About the experts
Dr. Stephen Pereira
Dr. Stephen Pereira is Professor of
Hepatology & Gastroenterology at University College London
since October 2016. He has been a Senior Lecturer then Reader
from 2003 and a Consultant Gastroenterologist in
PancreaticoBiliary Medicine at University College London Hospitals
from 2000. He undertook undergraduate studies in science
(theoretical physics) and medicine at University of New South Wales, Sydney, with postgraduate training mainly at
Guy's and King's College Hospital, London, and advanced endoscopy training (ERCP
and endoscopic ultrasound) in Paris, Amsterdam
and Indianapolis. Over the last several years he has
developed a clinical research programme aimed at improving the
diagnosis and treatment of patients with liver
and pancreaticobiliary malignancy and lead a clinical and
laboratory-based research group based at the Royal Free
Campus. Dr. Stephen Pereira's
research areas include Cancer Proteomics, Cancer Biomarker
Discovery and Hepatobiliary and pancreatic dysplasia and
malignancy.
Dr. James Farrell,
MBChB
Dr. James Farrell is an
internationally recognized expert in gastrointestinal endoscopy and
pancreatic diseases. He maintains a busy clinical practice focused
on all aspects of interventional endoscopy, gastrointestinal
cancer, and pancreatic diseases including endoscopic
retrograde cholangiopancreatography (ERCP) and endoscopic
ultrasound (EUS) evaluation of pancreatic cancer, pancreatic cysts,
pancreatitis, and individuals at risk for pancreatic
malignancy.
In addition to his clinical work and research, Dr. Farrell is
director of the Yale Medicine Pancreatic Diseases Program, which
brings together a variety of pancreatic specialists including
gastroenterologists, surgeons, oncologists, and nurses who
focus on pancreatic disease.
Dr. Farrell has addressed pancreatic disease on a national and
international level as a member of such organizations as the
NIH/NCI Pancreas Cancer Task Force. As a researcher, he is known
for his development of personalized therapy approaches and early
detection biomarkers for pancreatic cancer. Dr. James Farrell is professor of medicine
(digestive diseases) at Yale School of
Medicine.
Dr. Geoffrey Burns
A graduate of Brown University, Dr.
Geoffrey Burns received his medical
degree at Boston University School of
Medicine, a Top 25 medical school. Prior to establishing
Renaissance Family Medicine, Dr. Burns was the Associate Chairman
of Family Medicine at Newton-Wellesley Hospital and teaches at both
Boston University School of Medicine
and Tufts University School of
Medicine. Dr. Burns has also been named a Fellow of the
American Academy of Family Physicians, an honor given to members of
the Academy who have distinguished themselves among their
colleagues for their contributions to the practice of medicine and
to their communities. Dr. Burns devotes his personal time to
providing free medical care to underprivileged citizens in
South America and Appalachia. Dr.
Burns has the distinction of having been voted one of Boston's "Top Docs" in Family Medicine by
Boston Magazine in 2014 and 2015.
For more information, please contact:
Patrik Dahlen, CEO Immunovia
Email: patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1. The final
validation study was completed in Q1 2021. The accreditation
process forImmunovia Inc. in Marlborough, Massachusetts, USA is ongoing and commercial
testing will begin in Q2 after the accreditation. The European
launch plan will be communicated Q2 2021.
IMMray™ PanCan-d will be the first blood-based test for early
diagnosis of pancreatic cancer on the market, with a potential to
significantly improve patient survival and outcome. The test will
be exclusively provided by Immunovia Inc., Marlborough, Massachusetts, USA.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-to-host-a-key-opinion-leader-event-on-the-clinical-use-of-immray--pancan-d,c3355310
The following files are available for download:
https://mb.cision.com/Main/13121/3355310/1423811.pdf
|
Press release
(PDF)
|